Correlation Between CEA Serum Level on NSCLC Patients with EGFR Mutation from Tissue and Plasma Sample

Frenky Hardiyanto Hendro Sampurno, Suryanti Dwi Pratiwi, Ngakan Putu Parsama Putra

Abstract


Background: Patients with NSCLC can have EGFR mutation and increased level of CEA. EGFR mutation test on NSCLC has very important role for EGFR tyrosine kinase inhibitor (TKI) therapy.CEA is also expected to predict treatment efficiency of EGFR-TKI therapy. Tumor tissue biopsy is an invasive method and has come constraints, despite the golden standard testing. Circulating tumor DNA (ctDNA) is a new and less invasive for detecting EGFR mutation using plasma sample. In this study, we investigated the relationship between serum CEA and EGFR mutations in tissue and plasma in NSCLC patient.

Methods: This cross-sectional observational research was conducted in Dr. Saiful Anwar General Hospital Malang from August 2018 until July 2019, 76 NSCLC patients who had undergone test of EGFR mutation from tissue, ctDNA, and serum CEA level. Extracted DNA from plasma and tissue samples from citology or biopsy was checked for the EGFR mutation. The serum CEA levels were analyzed using electrochemical luminescence.

Results: EGFR mutation from tissue samples positive detected on 34 subjects and ctDNA detected 19 subjects. Serum level of CEA >5 ng/ml was significantly associated with EGFR mutation from tissue sample (p=0.037) with an odds ratio of 2.778 (95% CI: 1.050-7.348), the area under curve for CEA was 68,8% and cut-off CEA 9.14 ng/ml. Serum level of CEA >5 ng/ml wasalso significantly associated with ctDNA (p=0.015) with an odds ratio of 4.8 (95% CI: 1.259-18.299), the area under curve for CEA was 78,1% and cut-off CEA 14.8 ng/ml.

Conclusion: Serum CEA level has poor correlation with mutation of EGFR from tissue and moderate correlation with mutation of EGFR from ctDNA in NSCLC patients. Patients with increased level of CEA >5 ng/ml are 2.778 times more at risk to had EGFR mutation and 4.8 times more at risk to had ctDNA positive mutation.

Keywords


Lung Cancer, NSCLC, EGFR, ctDNA, CEA

Full Text:

PDF

References


Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M, Murad MH. Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Annals of thoracic medicine. 2013 Oct;8(4):204.

Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory investigation. 2014 Feb;94(2):129-37.

Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. Journal of thoracic disease. 2010 Mar;2(1):48.

Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG, Ethier SP. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. Journal of Thoracic Oncology. 2011 Mar 1;6(3):627-30.

Wang J, Li ZM, Ding X, Xu L, Xu Y, Qiu M, Jiang F, Yin R. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014 Dec 30.

Que D, Xiao H, Zhao B, Zhang X, Wang Q, Xiao H, Wang G. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer biology & therapy. 2016 Mar 3;17(3):320-7.

Bernabé R, Hickson N, Wallace A, Blackhall FH. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?. European Journal of Cancer. 2017 Aug 1;81:66-73.

Pan JB, Hou YH, Zhang GJ. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pacific Journal of Cancer Prevention. 2013;14(2):695-700.

Pan YQ, Shi WW, Xu DP, Xu HH, Zhou MY, Yan WH. Associations Between Epidermal Growth Factor Receptor Gene Mutation and Serum Tumor Markers in Advanced Lung Adenocarcinomas: A Retrospective Study. Chinese Medical Sciences Journal. 2014 Sep 1;29(3):156-61.

Normawati N, Pratiwi SD, Setijowati N. Epidermal Growth Factor Receptor (Egfr) and Carcinoembryonic Antigen (Cea) Relationship of Lung Adenokarsinoma in Saiful Anwar Hospita Malang. Berkala Kedokteran. 2017 Oct 13;13(2):173-81.

Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, Morabito A, Novello S, Arriola E, Molinier O, McCormack R. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. Journal of Thoracic Oncology. 2016 Oct 1;11(10):1682-9.

Gao Y, Song P, Li H, Jia H, Zhang B. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations. BMC cancer. 2017 Dec;17(1):484.

Feng Y, Zhou J, Chen S, Jiang Y, Zhou Y. Relationship between EGFR gene mutation and serum tumor biomarkers in advanced lung adenocarcinoma. Int J Clin Exp Pathol. 2016 Jan 1;9(1):250-5.

Herman, Suryanti DP, Ngakan PP. Nilai Diagnostik Pemeriksaan Mutasi EGFR Dengan Sampel Plasma Darah Dibandingkan Sampel Jaringan Pada Pasien NSCLC [thesis]. Malang: Fakultas Kedokteran Universitas Brawijaya; 2019

Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD, Zhang S. Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology. 2012 Mar;25(3):347-69.

Guan Y, Wang ZJ, Wang LQ, Hua DF, Liu J. Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples. Genet Mol Res. 2016 Apr 4;15(2):gmr-15027001.

Yang J, Lee OJ, Son SM, Woo CG, Jeong Y, Yang Y, Kwon J, Lee KH, Han HS. EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors. Cancer research and treatment: official journal of Korean Cancer Association. 2018 Jul;50(3):908.

Lv YL, Liu HB, Yuan DM, Zhou L, Jin SX, Song Y. Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation. TRANSLATIONAL CANCER RESEARCH. 2019 Aug 1;8(4):1027-34.

Guo N, Lou F, Ma Y, Li J, Yang B, Chen W, Ye H, Zhang JB, Zhao MY, Wu WJ, Shi R. Circulating tumor DNA detection in lung cancer patients before and after surgery. Scientific reports. 2016 Sep 19;6:33519.

Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H, Maehara Y. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007 Dec 15;110(12):2793-8.

Yang ZM, Ding XP, Pen L, Mei L, Liu T. Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers. Asian Pacific Journal of Cancer Prevention. 2014;15(8):3451-5.

Wang WT, Li Y, Ma J, Chen XB, Qin JJ. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4-ALK fusion gene in lung adenocarcinoma patients. Asian Pac J Cancer Prev. 2014 Jan 1;15(9):3927-32.

Abdurahman A, Anwar J, Turghun A, Niyaz M, Zhang L, Awut I. Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non small cell lung cancer patients in Northwest China. Molecular and clinical oncology. 2015 Jul 1;3(4):847-50.

Jin B, Dong Y, Wang HM, Huang JS, Han BH. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. Acta Pharmacologica Sinica. 2014 Mar;35(3):373-80.

Asad-Ur-Rahman FN, Saif MW. Elevated level of serum carcinoembryonic antigen (CEA) and search for a malignancy: a case report. Cureus. 2016 Jun;8(6).

Chung S. False-positive Elevations in Carcinoembryonic Antigen Levels at a Health Screening Center. Laboratory Medicine Online. 2019 Jul 1;9(3):146-52




DOI: https://doi.org/10.36497/jri.v42i2.299

Refbacks

  • There are currently no refbacks.




Copyright (c) 2022 Frenky Hardiyanto Hendro Sampurno, Suryanti Dwi Pratiwi, Ngakan Putu Parsama Putra


INDEXING & PARTNER

SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 

 

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org


An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License

Statcounter